In Q2 2025, Avoro Capital Advisors held 28 positions worth $5.5B. They exited 34. Their largest holding was ASND ($859.5M). Portfolio value shrank -11.9% versus the prior quarter.
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q2 2025?
Avoro Capital Advisors held 28 biotech stocks in their 13F portfolio in Q2 2025. Their top positions include ASND, UTHR, ARGX, MDGL, KRYS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q2 2025?
Avoro Capital Advisors's tracked biotech portfolio was worth $5.5B across 28 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q2 2025?
Avoro Capital Advisors did not initiate any new positions in Q2 2025, but increased 9 existing holdings.
What did Avoro Capital Advisors sell in Q2 2025?
Avoro Capital Advisors fully exited 34 positions in Q2 2025, including MCRB, TNGX, DSGN, MRSN, AMLX and 29 more. They also trimmed 17 existing positions.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisorsportfolio →